‹ All Posts
Prameela Balakkala

28th Jul · SEBI-Registered Analyst

Pfizer India Q1 FY26: Profit Growth, Margin Expansion

$PFIZER Social Media–Ready Post 📌 Pfizer India Q1 FY26 Results Net Profit: ₹2.04B vs ₹1.9B (YoY) ⬆️ EBITDA: ₹2.47B vs ₹2.1B (YoY) ⬆️ EBITDA Margin: 37.9% vs 34.8% (YoY) ⬆️ 📊 Fundamentals & Ratios Revenue: ~₹25.2B Net Profit: ~₹7.22B Debt-to-Equity: ~0.1 (low leverage) P/E Ratio: ~22–24 ROE: ~20% Dividend Yield: ~1.5% ⚠️ Risks Regulatory pricing pressure Rising R&D costs Competitive intensity EPS decline despite profit growth

#SectorBreakouts#HiddenGems#TrendingSectors#TimeToExit#PersonalFinance
560 likes·75 comments